|
Revenue
|
|
$143.1m
|
$284.1m
|
$799.2m
|
$883.0m
|
$288.9m
|
$259.2m
|
$185.7m
|
|
Cost of revenue
|
|
$66.8m
|
$79.6m
|
$140.6m
|
$169.0m
|
$148.7m
|
$150.9m
|
$151.8m
|
|
Gross profit (derived)
|
|
$76.3m
|
$204.4m
|
$658.7m
|
$714.0m
|
$140.2m
|
$108.3m
|
$34.0m
|
|
Research and development
|
|
$3.6m
|
$9.3m
|
$15.2m
|
$18.4m
|
$17.3m
|
$19.2m
|
$17.4m
|
|
Selling, general and administrative
|
|
$48.4m
|
$94.2m
|
$100.1m
|
$129.3m
|
$151.4m
|
$161.8m
|
$145.1m
|
|
Total operating expenses
|
|
$119.2m
|
$164.2m
|
$244.6m
|
$308.8m
|
$320.6m
|
$494.8m
|
$249.3m
|
|
Change in estimated fair value of contingent consideration
|
|
$322k
|
$0
|
$0
|
($7.8m)
|
($3.3m)
|
($2.0m)
|
$200k
|
|
Impairment of goodwill and long-lived assets
|
|
—
|
—
|
—
|
—
|
$0
|
$166.2m
|
$68.7m
|
|
Restructuring
|
|
—
|
—
|
$0
|
$0
|
$6.5m
|
($1.2m)
|
$17.8m
|
|
Loss from operations
|
|
$24.0m
|
$119.9m
|
$554.6m
|
$574.2m
|
($31.6m)
|
($235.6m)
|
($215.3m)
|
|
Interest income
|
|
—
|
$0
|
$0
|
$2.3m
|
$27.7m
|
$27.4m
|
$11.4m
|
|
Loss on extinguishment of debt
|
|
$0
|
($7.6m)
|
$0
|
($208k)
|
$0
|
($3.2m)
|
$0
|
|
Change in payable to related parties pursuant to the Tax Receivable Agreement
|
|
$0
|
$0
|
$6.1m
|
($4.1m)
|
$668.9m
|
($40k)
|
$0
|
|
Net loss
|
|
($5.2m)
|
$78.8m
|
$469.2m
|
$490.7m
|
($138.4m)
|
($259.6m)
|
($230.8m)
|
|
Net loss attributable to non-controlling interests
|
|
($731k)
|
($10.2m)
|
$287.2m
|
$270.5m
|
($19.3m)
|
($114.8m)
|
($100.0m)
|
|
Net loss attributable to Maravai LifeSciences Holdings, Inc.
|
|
($4.5m)
|
$89.0m
|
$182.0m
|
$220.2m
|
($119.0m)
|
($144.8m)
|
($130.8m)
|
|
(Loss) income before income taxes
|
|
($5.9m)
|
$81.7m
|
$530.8m
|
$551.5m
|
$617.7m
|
($261.5m)
|
($235.0m)
|
|
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - basic (in usd per share)
|
|
($0)
|
$7
|
$2
|
$2
|
($1)
|
($1)
|
($1)
|
|
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - diluted (in usd per share)
|
|
($0)
|
$2
|
$2
|
$2
|
($1)
|
($1)
|
($1)
|
|
Weighted average Class A common shares outstanding—basic (in shares)
|
|
253.9m
|
10.4m
|
114.8m
|
131.5m
|
131.9m
|
137.9m
|
144.4m
|
|
Weighted average Class A common shares outstanding - diluted (in shares)
|
|
253.9m
|
28.9m
|
257.8m
|
255.3m
|
131.9m
|
137.9m
|
144.4m
|
|
Interest expense
|
|
($30.0m)
|
($30.7m)
|
($30.3m)
|
($20.4m)
|
($45.9m)
|
($47.7m)
|
($27.0m)
|
|
Other expense
|
|
$118k
|
$126k
|
$279k
|
($358k)
|
($1.3m)
|
($2.3m)
|
($4.2m)
|
|
Income tax (benefit) expense
|
|
($652k)
|
$2.9m
|
$61.5m
|
$60.8m
|
$756.1m
|
($1.9m)
|
($4.2m)
|